ROCKVILLE, Md., May 3 /PRNewswire/ -- Accelovance, a Rockville,
Maryland based clinical services company is pleased to name Robert C.
deGroof, Ph.D. as Chief Scientific Officer. In this role, Dr. deGroof will
bring his 25 years of pharmaceutical industry experience to lead all
clinical and regulatory services for current and upcoming research studies.
"We are excited to have Bob formally join us from his previous
consultant role. His experience with pharma and biotech will help position
our company to deliver a higher level of service to our clients and
strengthen our core competencies. This addition is an integral step in
moving Accelovance into its next phase of growth," remarked Stephen J.
Trevisan, CEO and President of Accelovance.
Before arriving at Accelovance, Dr. deGroof served as Senior Vice
President of Drug Development for Ambit Biosciences where he managed
clinical, toxicology, manufacturing, quality assurance and regulatory
affairs for all of their products. He had similar responsibilities as the
Senior Vice President of Scientific Affairs at Alteon Inc. Prior to Alteon,
Inc., he held leadership positions in drug development and regulatory
affairs at Johnson and Johnson and Bristol-Myers Squibb. Additionally, for
more than 10 years Dr. deGroof operated an independent consultancy for
strategic development of prescription and non-prescription pharmaceuticals.
Dr. deGroof held academic appointments at the medical schools of the
University of Pennsylvania and Thomas Jefferson University. He holds a
Ph.D. in Physiology and Pharmacology from Duke University and a B.S. in
Electrical Engineering from the University of Florida.
"It is exciting to join an entrepreneurial and client focused company
like Accelovance. My goal is to help deliver on our client's needs and
expand our service offerings over time," commented Dr. deGroof on his new
Headquartered in Rockville, Maryland, Accelovance is a privately held
company that has developed a unique system for delivering quality, on time,
and cost effective clinical studies. In China, the Company operates through
its wholly-owned foreign enterprise in Beijing as a contract research
organization (CRO). Accelovance is focused on optimizing the quality and
productivity of multiple clinical sites, through strong central management
and targeted pro-active patient recruitment. Delivering high quality and
timely clinical trial support services, Accelovance is committed to
understanding and meeting its clients needs to contribute to their success.
For more information, visit the company's website at
CONTACT: Media: Garrett D. Smith at 240.238.4914